223 results on '"Hofma, Sjoerd H."'
Search Results
2. Comparison of Supraflex Cruz 60 μm Versus Ultimaster Tansei 80 μm Stent Struts in High Bleeding Risk PCI Patients: Study design and Rational of Compare 60/80 HBR trial
3. The Supreme Biodegradable Polymer DES in Acute and Chronic Coronary Syndromes: A PIONEER III Substudy
4. Geographic Variations on the Safety and Efficacy of the Supreme Biodegradable Polymer DES: Results From PIONEER III
5. Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design
6. Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction
7. A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial
8. The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial
9. Everolimus eluting stent vs first generation drug-eluting stent in primary angioplasty: A pooled patient-level meta-analysis of randomized trials
10. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy
11. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent)
12. Outcome After ST Elevation Myocardial Infarction in Patients With Cancer Treated With Primary Percutaneous Coronary Intervention
13. Influence of Gender on Ischemic Times and Outcomes After ST-Elevation Myocardial Infarction
14. The Impact of Patient and Lesion Complexity on Clinical and Angiographic Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents: A Substudy of the RESOLUTE All Comers Trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention)
15. The Prognostic Utility of the SYNTAX Score on 1-Year Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents: A Substudy of the RESOLUTE All Comers Trial
16. Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry
17. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction—TROFI II trial
18. The Influence of Implantation Techniques on Lesion-Oriented Outcomes in Absorb BVS and Xience EES Lesions Treated in Routine Clinical Practice at Complete Three-Year Follow-Up - AIDA Trial QCA Substudy
19. Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients
20. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial
21. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents
22. Outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents by coronary complexity: a sub-analysis of the AIDA trial
23. Three‐year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus‐eluting stent in routine PCI in patients with diabetes mellitus— AIDA sub‐study
24. Final 3-Year Outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent
25. A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trial
26. The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy
27. Four-Year Follow-Up of Absorb BVS Compared to Xience EES in Daily Clinical Practice Shows Continued Accrual of Events
28. TCT-636 Impact of Diabetes on the Outcomes in Patients Undergoing Contemporary Percutaneous Coronary Intervention: Analysis From the GLOBAL LEADERS Study
29. TCT-41 A Prospective Multicenter Randomized All-Comers Trial to Assess the Safety and Effectiveness of the Ultra-Thin-Strut Sirolimus-Eluting Coronary Stent Supraflex: 2-Year Results of the TALENT Trial
30. TCT-164 Clinical Outcomes at 3 Years of the Absorb Bioresorbable Vascular Scaffold Versus Xience Drug-Eluting Metallic Stent in Patients With or Without Acute Coronary Syndrome: AIDA Trial Substudy
31. TCT-320 Prophylactic Veno-Arterial–Extracorporeal Membrane Oxygenation in Patients Undergoing High-Risk Percutaneous Coronary Interventions
32. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial
33. Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents
34. Three‐year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus‐eluting stent in routine PCI in patients with diabetes mellitus—AIDA sub‐study.
35. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation
36. Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions
37. Safety and efficacy of everolimus- versus sirolimus-eluting stents: A systematic review and meta-analysis of 11 randomized trials
38. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction
39. No change in endothelial-dependent vasomotion late after coronary irradiation
40. Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug‐eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy
41. CLINICAL OUTCOMES AT 2 YEARS OF THE ABSORB BIORESORBABLE VASCULAR SCAFFOLD VERSUS THE XIENCE DRUG-ELUTING METALLIC STENT IN PATIENTS PRESENTING WITH ACUTE CORONARY SYNDROME VERSUS STABLE CORONARY DISEASE: AIDA TRIAL SUB-STUDY
42. 500.02 Clinical Outcomes At 2 Years of The Absorb Bioresorbable Vascular Scaffold Versus The Xience Drug-eluting Metallic Stent In Patients Presenting With Acute Coronary Syndrome Versus Stable Coronary Disease - Aida Trial Sub-study.
43. Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)
44. Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug‐eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy.
45. Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI
46. Bioresorbable Scaffolds versus Metallic Stents in Routine PCI
47. TCT-430 Baseline and procedural characteristics in the Amsterdam Investigator-initiateD randomized Absorb Trial
48. TCT-161 5 years follow-up of biolimus eluting stents versus everolimus eluting in ST-segment elevation myocardial infarction presenting patients: Results from Compare II trial
49. TCT-472 Comparison biolimus- and everolimus-eluting stents in patients with complex lesions. Five year follow-up from the COMPARE II trial
50. TCT-264 Abluminal biodegradable polymer biolimus-eluting versus durable polymer everolimus-eluting stent in patients with diabetes. 5 years follow-up from the COMPARE II trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.